The head and shoulders pattern successfully played out, with 
NOVO_B reaching my full target at 670.
Check out my original post:
The stock experienced a significant drop, falling as much as 27% on the Friday before Christmas. This was triggered by test results for their obesity drug, CagriSema, which showed patient weight loss of 22.7% - below the anticipated 25%.
I believe this reaction is an overcorrection and have taken advantage of this rare opportunity to purchaseNOVO_B, first at 680 and again at 600. I now plan to hold patiently, expecting Novo Nordisk to reach new all-time highs in the coming years.
NOVO_B reaching my full target at 670.Check out my original post:
The stock experienced a significant drop, falling as much as 27% on the Friday before Christmas. This was triggered by test results for their obesity drug, CagriSema, which showed patient weight loss of 22.7% - below the anticipated 25%.
I believe this reaction is an overcorrection and have taken advantage of this rare opportunity to purchase
NOVO_B, first at 680 and again at 600. I now plan to hold patiently, expecting Novo Nordisk to reach new all-time highs in the coming years.
Penerbitan berkaitan
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penerbitan berkaitan
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.